Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib for Corneal Neovascularization
NCT01257750Phase 2Completed
- Start
- Nov 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in corneal neovascularization (CNV). Primary endpoints: Heart Rate at 12 weeks, Mean Arterial Pressure at 12 weeks and 2 more. Started Nov 2010; status: completed.
02
Drugs
pazopanib
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on NCT01257750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01257750.